Novartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen's technology for turning intravenous biologics ...
Italian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 ...
French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a ...
A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to ...
Swiss biotech NovaGo Therapeutics has raised CHF 24 million ($30 million/€25.5 million) in a Series B round to advance its ...
Novartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another ...
Roche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results